Pharnext Takes a Unique Twist on Repurposing Drugs for Rare Diseases
January 12, 2018
Repurposing, finding new uses for already approved drugs, has long been viewed as a way bring needed therapies to rare disease patients that’s fast and cost-effective. Pharnext is putting a new twist on repurposing by using genomic data and network pharmacology to identify thousands of molecules that may be involved in a disease and finding synergistic combinations of available therapies to treat it. We spoke to Daniel Cohen, CEO of Pharnext, about its so-called Pleotherapy, how it goes about finding and formulating combinations of drugs, and why this may hold greater promise than traditional repurposing approaches.
Sign up for updates straight to your inbox.